Draft Patents (Amendment), Rules, 2023
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
THE second part of Frontline's interview with David Baltimore, the reputed American biologist and Nobel laureate, includes a discussion on a wide range of issues including his own research; funding
Thailand's new government will override international patents on three cancer drugs, Chaiya Sasomsap, the new health minister said yesterday, after a month of protests against his review of the policy
a patent dispute between pharma companies over a migrane drug in the us market has been settled out of court. Ranbaxy, one of the world's largest producers of generic drugs, announced through a
Company plans to sell Flame with single spark plug Stressing "there is no injunction against selling the
India has performed poorly in international patent filings last year compared to its neighbour China, according to data released by the Geneva-based World Intellectual Property Organisation (WIPO). Filing patent applications under WIPO's Patent Cooperation Treaty (PCT) enables companies to secure patent protection in various countries. It is a measure for a knowledge-based economy and a barometer of the spread of innovation-based companies in each country. In the global race for knowledge-based industries, WIPO's data clearly suggest that India is far behind China. India, for example, filed only 686 applications last year to secure patent protection in countries that are members of the PCT compared to 831 in 2006. In the same period China's patent applications grew 38.1 per cent to reach an all-time high 5,456. China's impressive growth in its innovation-based companies enabled the Middle Kingdom to occupy seventh place in the world's top 15 countries. "We expect India to grow rapidly in life-sciences research, but at this juncture its considerable research and development activity has not translated into patent filings,' said Francis Gurry, deputy-director general at WIPO overseeing the PCT work. The stark differences between these two big economies are due to the underlying differences in their overall economic activity. While software and services dominate the Indian economy, new manufacturing activities are at the centre of the Chinese miracle, Gurry said. Until now, the industrialised countries
The Biotechnology Industry Association (BIA), the representative body of international biotech product makers, has expressed concern over the patent criteria norms prescribed under the Indian Patent Act. In a representation to the office of the US Trade Representative (USTR) on February 11, the association has demanded that India be kept under the priority watch list of USTR due to inadequate intellectual property (IP) compliance.
The government must encourage the manufacture of cheaper drugs which will benefit the consumer. Till the early 1980's, dominant foreign companies dominated pharmaceutical manufacturing in India. Today the dominant ones are Indian owned. The then Indian patent laws helped this transformation. Until recently India recognised only process patents. Reverse engineering by Indian pharmaceutical chemists enabled Indian companies to replicate popular foreign drugs through different processes and market them in India.
When pharmaceutical company Novartis challenged the rejection of its patent application for the leukemia drug Gleevec in Novartis AG v. Union of India, it became the first major legal challenge to India’s
lipitor patent revoked: Pfizer Inc said on October 29 a German court had revoked the drugmaker's patent covering the active ingredient in its blockbuster cholesterol drug Lipitor. The decision
the verdict is heavy on symbolism. The Madras High Court dismissed a petition by pharmaceutical giant Novartis challenging section 3d of the Indian Patent (Amendments) Act 2005. Human rights groups